长期从事离子通道与心脑血管疾病发病关系的研究。主要贡献：(1)阐明了心血管系统容积调节性氯通道和钙激活氯通道的分子基础，明确了氯通道是防治心血管疾病的新靶点（Circulation,Hypertension）；（2）揭示了氯通道调控心血管功能的作用机理，提出“Cl- 可能是胞内信号途径的重要调控分子”的新观点（Hypertension,Gut）；（3）发现抑制ClC-3氯通道和miR-155表达是他汀类药物保护心血管功能的重要机制，为他汀类药物的非降脂效应提供了新的作用机理（Hypertension）。这些研究明确了氯通道是心血管功能稳态的关键调控分子，为进一步以氯通道为靶点的抗心血管疾病新药研发提供了重要理论依据。近5年共发表SCI论著20篇，包括（共同）通讯作者7篇，第一作者2篇；3篇IF﹥7，2篇IF﹥13。拟进一步开展氯通道功能及调控机制研究，并明确Cl-调控胞内信号的分子机制。

The work in my lab mainly focuses on the contributions of chloride channels to cardiovascular diseases. We found that ClC-3 and TMEM16A are the counterparts of volume-regulated chloride channel and calcium-activated chloride channel, respectively, and revealed that ClC-3 and TMEM16A chloride channels are the potential therapeutic targets for cardiovascular diseases. In addition, we reported that activation of chloride channels would result in decrease of intracellular Cl- concentration, and proposed the hypothesis that Cl- may be an important second messenger in regulation of cardiovascular homeostasis. Moreover, we found that inhibition of volume-regulated chloride channel and miR-155 expression underlie the beneficial effects of statins on cardiovascular system. Altogether, applicant has published 20 papers in SCI journals, including 7 papers as (co)corresponding author, 2 papers as the first author. Among these papers, 3 papers: impact factor>7, 2 papers: impact factor>13. Basis on our previous results and recent progress in this field, we are going to further investigate the regulatory mechanisms of the activation of chloride channels during hypertension and atherosclerosis, and provide further evidence to test the possibility that chloride serves as a intracellular second messenger. The long term goal of my lab is to provide evidence to support the hypothesis that chloride channels are novel therapeutic targets for cardiovascular diseases.